Ovarian Cancer Canada

Western Regional Blog – BC, YK, AB, NWT and Nunavut

Quality of Life and Treatment Response among Women with Platinum-resistant versus Platinum-sensitive Ovarian Cancer Treated for Progression: A Prospective Analysis

Highlights Quality of Life (QoL) may be maintained in women re-treated for platinum-resistant ovarian cancer. Treatment response appears better if re-treated with platinum-based agents. QoL at chemotherapy start may be higher in women who have a response. 

Vanessa L. Beesley, Adele C. Green, David K. Wyld, Peter O’Rourke, Leesa F. Wockner, Anna deFazio, Phyllis N. Butow, Melanie A. Price, Keith R. Horwood, Alexandra M. Clavarino, Australian Ovarian Cancer Study Group, Australian Ovarian Cancer Study-Quality of Life Study Investigators, Penelope M. Webb



Objective Most women with ovarian cancer relapse and undergo further chemotherapy however evidence regarding the benefits of this for women with platinum-resistant disease is limited. Our objective was to determine whether there was a quality of life improvement or treatment response among women treated for platinum-resistant recurrent ovarian cancer.

Methods We combined data from 2 studies where women treated with chemotherapy for recurrent ovarian cancer (n = 172) completed a quality of life questionnaire every 3 months. Cancers were classified as platinum-resistant if they progressed within 6 months of completing first-line chemotherapy. Mixed effects models were used to analyse change in quality of life during the first 6 months after second-line chemotherapy.

Results One-quarter of women (n = 44) were classified as having platinum-resistant disease. Overall, their quality of life did not significantly increase or decrease, following commencement of second-line chemotherapy (least square mean scores = 107, 105, 103 at chemotherapy start, 3 and 6 months later, respectively), although 26% of these women reported a meaningful increase and 31% reported a meaningful decline. One-third of the platinum-resistant group responded (11% complete and 21% partial response) to second-line chemotherapy, and this figure increased to 54% among the subset (36%) re-treated with platinum-based agents with or without other agents. Preliminary analyses suggest quality of life may be higher at chemotherapy initiation in women whose disease responded (median score 121 vs 110).

Conclusions Overall, quality of life appears to be maintained in women with platinum-resistant ovarian cancer who receive further chemotherapy and some women respond to re-treatment.


This entry was posted on November 4, 2013 by in Research Updates and tagged , , , .

Complementary and Alternative Therapies


Research in BC

The Injustices of Ovarian Cancer

Ovarian Cancer Canada

%d bloggers like this: